AI Engines For more Details: Perplexity Kagi Labs You
Endometriosis: Danazol is used in the treatment of endometriosis, a condition in which the tissue that normally lines the inside of the uterus (endometrium) grows outside the uterus, leading to pelvic pain, infertility, and other symptoms. Danazol suppresses the growth of endometrial tissue by inhibiting ovarian function, reducing estrogen levels, and inducing a hypoestrogenic state. It helps alleviate symptoms such as pelvic pain, dysmenorrhea (painful periods), and dyspareunia (pain during intercourse) associated with endometriosis.
Fibrocystic Breast Disease: Danazol is also used in the treatment of fibrocystic breast disease, a benign breast condition characterized by the development of cysts, nodules, and breast pain. Danazol helps reduce breast pain and tenderness by suppressing the proliferation of breast tissue and decreasing the size and number of breast cysts. It may also alleviate symptoms such as breast swelling and discomfort associated with fibrocystic changes.
Hereditary Angioedema (HAE): Danazol is indicated for the prevention of attacks in hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling in various parts of the body, including the skin, gastrointestinal tract, and airway. Danazol helps prevent angioedema attacks by increasing the levels of C1 inhibitor, a protein involved in regulating the complement pathway and preventing excessive inflammation and swelling.
Dosage and Administration: Danazol is typically administered orally in the form of capsules or tablets. The dosage and duration of treatment depend on the specific medical condition being treated, the severity of symptoms, and the individual patient's response to therapy. It is important to follow the dosage instructions provided by the healthcare provider and to take danazol as directed to achieve optimal therapeutic outcomes.
Side Effects: Common side effects of danazol may include weight gain, fluid retention, acne, oily skin, hirsutism (excessive hair growth), voice changes, menstrual irregularities, and hot flashes. Long-term use of danazol may be associated with more serious side effects such as hepatic dysfunction, lipid abnormalities, and increased risk of cardiovascular events. Patients should be monitored regularly for side effects during danazol therapy, and treatment should be adjusted as needed based on individual response and tolerance.
Contraindications and Precautions: Danazol is contraindicated in pregnant women, breastfeeding mothers, and individuals with a history of hormone-sensitive cancers, liver disease, or thromboembolic disorders. It should be used with caution in patients with cardiovascular risk factors, as it may increase the risk of cardiovascular events such as myocardial infarction and stroke. Before starting danazol therapy, patients should undergo a thorough medical evaluation, including assessment of liver function, lipid profile, and cardiovascular risk factors.
Rank | Probiotic | Impact |
---|---|---|
species | Akkermansia muciniphila | Reduces |
species | Bifidobacterium adolescentis | Reduces |
species | Bifidobacterium longum | Reduces |
species | Lacticaseibacillus paracasei | Reduces |
subspecies | Bifidobacterium longum subsp. infantis | Reduces |
subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0.1 | 0.1 | |
Acne | 0.4 | -0.4 | |
ADHD | 4.2 | 0.5 | 7.4 |
Age-Related Macular Degeneration and Glaucoma | 0.7 | 0.4 | 0.75 |
Allergic Rhinitis (Hay Fever) | 1.4 | 1.8 | -0.29 |
Allergies | 4.3 | 2.2 | 0.95 |
Allergy to milk products | 0.6 | 0.7 | -0.17 |
Alopecia (Hair Loss) | 1.7 | 1.7 | |
Alzheimer's disease | 2.5 | 3.3 | -0.32 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.9 | 0.8 | 2.62 |
Ankylosing spondylitis | 2.7 | 1.3 | 1.08 |
Anorexia Nervosa | 0.4 | 1.4 | -2.5 |
Antiphospholipid syndrome (APS) | 0.6 | 0.1 | 5 |
Asthma | 1.2 | 1.4 | -0.17 |
Atherosclerosis | 0.9 | 1.5 | -0.67 |
Atrial fibrillation | 2.6 | 1.3 | 1 |
Autism | 7.2 | 6.6 | 0.09 |
Barrett esophagus cancer | 0.3 | 0.2 | 0.5 |
Bipolar Disorder | 0.8 | 1.1 | -0.38 |
Brain Trauma | 0.6 | 0.4 | 0.5 |
Carcinoma | 3 | 2.4 | 0.25 |
Celiac Disease | 0.9 | 3.7 | -3.11 |
Cerebral Palsy | 1.2 | 1 | 0.2 |
Chronic Fatigue Syndrome | 4.6 | 5.3 | -0.15 |
Chronic Kidney Disease | 1.5 | 0.9 | 0.67 |
Chronic Lyme | 0.4 | -0.4 | |
Chronic Obstructive Pulmonary Disease (COPD) | 1.2 | 0.6 | 1 |
Chronic Urticaria (Hives) | 0.5 | 1.3 | -1.6 |
Coagulation / Micro clot triggering bacteria | 0.5 | 1 | -1 |
Colorectal Cancer | 2.6 | 0.6 | 3.33 |
Constipation | 0.5 | 0.6 | -0.2 |
Coronary artery disease | 1.1 | 0.6 | 0.83 |
COVID-19 | 10.1 | 10 | 0.01 |
Crohn's Disease | 5.6 | 4.2 | 0.33 |
cystic fibrosis | 0.8 | -0.8 | |
deep vein thrombosis | 0.6 | -0.6 | |
Depression | 8 | 5.9 | 0.36 |
Dermatomyositis | 0.2 | 0.4 | -1 |
Eczema | 0.8 | 1.4 | -0.75 |
Endometriosis | 2 | 0.9 | 1.22 |
Eosinophilic Esophagitis | 0.1 | 0.2 | -1 |
Epilepsy | 2.1 | 3 | -0.43 |
Fibromyalgia | 2.8 | 1.8 | 0.56 |
Functional constipation / chronic idiopathic constipation | 3.6 | 1.8 | 1 |
gallstone disease (gsd) | 1.7 | 0.7 | 1.43 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.7 | 0.9 | -0.29 |
Generalized anxiety disorder | 1.1 | 1.6 | -0.45 |
giant cell arteritis | 0.2 | -0.2 | |
Glioblastoma | 0.2 | -0.2 | |
Gout | 0.1 | -0.1 | |
Graves' disease | 1.2 | 1.2 | 0 |
Halitosis | 0.5 | 0.2 | 1.5 |
Hashimoto's thyroiditis | 1.9 | 0.6 | 2.17 |
Hidradenitis Suppurativa | 0.3 | 0.2 | 0.5 |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 2.2 | 0.7 | 2.14 |
hypercholesterolemia (High Cholesterol) | 0.5 | 0.6 | -0.2 |
hyperglycemia | 2.2 | -2.2 | |
Hyperlipidemia (High Blood Fats) | 0.9 | 0.2 | 3.5 |
hypersomnia | 0.4 | -0.4 | |
hypertension (High Blood Pressure | 1.9 | 4.4 | -1.32 |
Hypothyroidism | 1.2 | -1.2 | |
Hypoxia | 0.9 | 0.9 | |
IgA nephropathy (IgAN) | 3.2 | -3.2 | |
Inflammatory Bowel Disease | 3.1 | 6 | -0.94 |
Insomnia | 0.7 | 0.7 | 0 |
Intelligence | 0.8 | 0.3 | 1.67 |
Intracranial aneurysms | 1.1 | 0.2 | 4.5 |
Irritable Bowel Syndrome | 2.2 | 3.4 | -0.55 |
Liver Cirrhosis | 3.5 | 2.4 | 0.46 |
Long COVID | 5.1 | 6.8 | -0.33 |
Low bone mineral density | 0.6 | -0.6 | |
Lung Cancer | 0 | 1.6 | 0 |
ME/CFS with IBS | 0.7 | 2.3 | -2.29 |
ME/CFS without IBS | 2.1 | 2.5 | -0.19 |
Menopause | 2.1 | 2.1 | |
Metabolic Syndrome | 5.4 | 7.4 | -0.37 |
Mood Disorders | 9.9 | 6.2 | 0.6 |
multiple chemical sensitivity [MCS] | 1 | 0.3 | 2.33 |
Multiple Sclerosis | 5.4 | 3.5 | 0.54 |
Multiple system atrophy (MSA) | 2.1 | 0.9 | 1.33 |
Neuropathy (all types) | 0.8 | 0.8 | |
neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.6 | 4.5 | -1.81 |
NonCeliac Gluten Sensitivity | 0.4 | -0.4 | |
Obesity | 6.5 | 4 | 0.63 |
obsessive-compulsive disorder | 4.7 | 3.3 | 0.42 |
Osteoarthritis | 1.7 | 0.2 | 7.5 |
Osteoporosis | 1.1 | 1.2 | -0.09 |
pancreatic cancer | 0.5 | 0.5 | |
Parkinson's Disease | 2.6 | 2.2 | 0.18 |
Polycystic ovary syndrome | 1.3 | 1.8 | -0.38 |
Postural orthostatic tachycardia syndrome | 0.2 | 0.5 | -1.5 |
Premenstrual dysphoric disorder | 0.9 | 0.4 | 1.25 |
primary biliary cholangitis | 0.4 | 0.8 | -1 |
Psoriasis | 3.4 | 2.5 | 0.36 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 5.1 | 2.7 | 0.89 |
Rosacea | 0.6 | 0.4 | 0.5 |
Schizophrenia | 5.9 | 1.5 | 2.93 |
scoliosis | 0.1 | 0.7 | -6 |
Sjögren syndrome | 1.9 | 2.9 | -0.53 |
Sleep Apnea | 1.1 | 1.2 | -0.09 |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.3 | 0.7 | -1.33 |
Stress / posttraumatic stress disorder | 2.2 | 2.5 | -0.14 |
Systemic Lupus Erythematosus | 3.1 | 1.7 | 0.82 |
Tic Disorder | 0.5 | 1.3 | -1.6 |
Tourette syndrome | 0.3 | 0.2 | 0.5 |
Type 1 Diabetes | 2.2 | 1.6 | 0.38 |
Type 2 Diabetes | 5.3 | 5 | 0.06 |
Ulcerative colitis | 1.7 | 4.3 | -1.53 |
Unhealthy Ageing | 3.6 | 1.4 | 1.57 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.